| Product vision |
- Intermittent preventive treatment (TPP-1) and prophylaxis (TPP-2)
|
| MoA |
- Interfere with two pathways involved in the biosynthesis of pyrimidines required for nucleic acid replication
- Atovaquone acts against P. falciparum via inhibition of mitochondrial electron transport
|
| Key features |
- Liver-stage activity and prophylactic efficacy
- Lower doses of atovaquone required in the combination leading to lower cost of goods
|
| Challenges |
- To obtain comparable bioavailability
|
| Status |
- Relative bioavailability study between atoguanil and atovaquone-proguanil to be set-up
|
| Next milestone |
|
| MMV Project Director |
- Dr Isabelle Borghini Fuhrer
|
